Telix Pharmaceuticals (TLX) Price & Analysis

Compare

493 Followers

TLX Stock Chart & Stats

AU$14.00

-AU$0.59(-2.38%)

At close: Jan 09 4:00 PM EST

AU$14.00

-AU$0.59(-2.38%)

Day’s Range― - ―

52-Week RangeAU$13.30 - AU$31.97

Previous CloseN/A

Volume456.62K

Average Volume (3M)1.36M

Market Cap

$4.94B

Enterprise ValueAU$8.56B

Total Cash (Recent Filing)$207.16M

Total Debt (Recent Filing)$418.25M

Price to Earnings (P/E)287.6

Beta1.23

Next Earnings

Feb 19, 2026

EPS Estimate

0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.01

Shares Outstanding338,721,340

10 Day Avg. Volume1,165,560

30 Day Avg. Volume1,362,129

Financial Highlights & Ratios

PEG Ratio0.20

Price to Book (P/B)14.35

Price to Sales (P/S)10.41

P/FCF Ratio906.02

Enterprise Value/Market Cap1.73

Enterprise Value/Revenue7.21

Enterprise Value/Gross Profit12.69

Enterprise Value/Ebitda99.84

Forecast

1Y Price Target

$28.05

Price Target Upside100.38% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Guidance IncreaseThe company increased total revenue guidance by $25MM at the midpoint to $800-820MM, indicating confidence in future performance.

Product Approval And ReimbursementKey catalysts include the potential approval of Zircaix in the US and confirmation of US CMS transitional pass-through status for Gozellix.

Revenue GrowthTelix pre-reported Q3 total revenue of $206MM, ahead of expectations as the PSMA diagnostic franchise volume grew +3%.

Bears Say

Operating CostsHigher-than-expected operating costs relative to consensus expectations.

Pricing PressureThe 3% volume increase in PSMA diagnostics was offset by expected pricing pressure that was likely driven by Illuccix's loss of transitional pass-through status and competition.

Share Price DeclineTLX's share price has declined by 28% from 22 Jul-25, underperforming the ASX200 by 32%.

Telix Pharmaceuticals News

Telix Pharmaceuticals Advances Prostate Cancer Therapy with Phase 3 Trial Expansion

Telix Pharmaceuticals ( ($AU:TLX) ) has provided an announcement. Telix Pharmaceuticals has announced the dosing of the first...

4d ago

Telix Pharmaceuticals to Release Shares from Voluntary Escrow

An announcement from Telix Pharmaceuticals ( ($AU:TLX) ) is now available. Telix Pharmaceuticals announced the release of 45,584...

1M ago

Telix Pharmaceuticals to Release Shares from Voluntary Escrow

Telix Pharmaceuticals ( ($AU:TLX) ) has issued an update. Telix Pharmaceuticals announced the release of 1,649,037 ordinary shares...

2M ago

Telix Pharmaceuticals: Strong Q3 Performance and Strategic Positioning Reinforce Buy Rating

Telix Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tara Bancroft from...

2M ago

Telix Pharmaceuticals Boosts Revenue Forecast Amid Strategic Expansions

Telix Pharmaceuticals ( ($AU:TLX) ) has issued an update. Telix Pharmaceuticals reported a significant revenue increase of 53%...

2M ago

Telix Pharmaceuticals Announces Cessation of Securities

Telix Pharmaceuticals ( ($AU:TLX) ) just unveiled an update. Telix Pharmaceuticals Limited announced the cessation of certain securities,...

2M ago

Telix Pharmaceuticals Issues New Securities to Bolster Strategic Growth

Telix Pharmaceuticals ( ($AU:TLX) ) just unveiled an announcement. Telix Pharmaceuticals Limited announced the issuance of 80,000 ordinary...

2M ago

Telix Pharmaceuticals Expands ASX Quotation with New Securities

Telix Pharmaceuticals ( ($AU:TLX) ) has issued an update. Telix Pharmaceuticals Limited has announced the quotation of new...

2M ago

Telix Pharmaceuticals Secures Key Reimbursement Status for Gozellix

An update from Telix Pharmaceuticals ( ($AU:TLX) ) is now available. Telix Pharmaceuticals announced that the U.S. Centers...

3M ago

Challenger Limited Ceases Substantial Holding in Telix Pharmaceuticals

Telix Pharmaceuticals ( ($AU:TLX) ) has shared an announcement. Challenger Limited has announced that it has ceased to...

3M ago

Telix Pharmaceuticals announces Health Canada approval of Illuccix

Telix Pharmaceuticals announces that Health Canada has approved the use of Illuccix in selecting patients for PSMA1-targeted radionuclide...

1y ago

Telix Pharmaceuticals announces first patient dosed in Phase II CA-NINE trial

Telix Pharmaceuticals announces that the first patient has been dosed in a Phase II trial exploring the clinical...

1y ago

Telix Pharmaceuticals to acquire RLS

Telix Pharmaceuticals and RLS, America’s only Joint Commission-accredited radiopharmacy network distributing PET1, SPECT2 and therapeutic radiopharmaceuticals, announced an...

1y ago

Telix announces Cardinal Health as U.S. commercial distributor for Zircaix

Telix Pharmaceuticals has selected Cardinal Health as a commercial radiopharmaceutical distributor to supply finished unit doses of its...

1y ago

CAH

TLX FAQ

What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?

Telix Pharmaceuticals Ltd. lowest share price was AU$13.30 and its highest was AU$31.97 in the past 12 months.

What is Telix Pharmaceuticals Ltd.’s market cap?

Telix Pharmaceuticals Ltd.’s market cap is $4.94B.

When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?

Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Feb 19, 2026 which is in 70 days.

How were Telix Pharmaceuticals Ltd.’s earnings last quarter?

Telix Pharmaceuticals Ltd. released its earnings results on Aug 20, 2025. The company reported AU$0.015 earnings per share for the quarter, missing the consensus estimate of AU$0.276 by -AU$0.261.

Is Telix Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Telix Pharmaceuticals Ltd. pay dividends?

Telix Pharmaceuticals Ltd. does not currently pay dividends.

What is Telix Pharmaceuticals Ltd.’s EPS estimate?

Telix Pharmaceuticals Ltd.’s EPS estimate is 0.07.

How many shares outstanding does Telix Pharmaceuticals Ltd. have?

Telix Pharmaceuticals Ltd. has 338,721,340 shares outstanding.

What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?

Telix Pharmaceuticals Ltd. reported an EPS of AU$0.015 in its last earnings report, missing expectations of AU$0.276. Following the earnings report the stock price went up 6.974%.

Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:TLX

Telix Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

3.21%

Trailing 12-Months

Asset Growth

138.86%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals (TLX) is a biopharmaceutical company focused on the development and commercialization of innovative medicines for the treatment of cancer and other serious diseases. The company specializes in radiopharmaceuticals, which are a combination of pharmaceuticals and radioactive isotopes, aimed at targeting and treating tumors while minimizing damage to surrounding healthy tissue. Telix operates primarily in the oncology sector, with a portfolio that includes products designed for imaging and therapeutic applications, such as prostate cancer and renal cancers.

Telix Pharmaceuticals (TLX) Earnings & Revenues

Historic Earnings Reports

TLX Company Deck

TLX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a strong performance in terms of revenue growth, product expansion, and strategic acquisitions, highlighting the company's robust cash position and pipeline advancements. However, challenges such as SEC inquiries, gross margin pressure, and competitive pricing pressures were noted.View all AU:TLX earnings summaries

TLX Stock 12 Month Forecast

Average Price Target

AU$28.05

▲(100.38% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"AU$13","36":"AU$36","18.75":"AU$18.75","24.5":"AU$24.5","30.25":"AU$30.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35.206558891441,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$35.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.0537256396,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$28.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.73337802704476,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$22.73</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,18.75,24.5,30.25,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.05,16.600504530110847,18.151009060221693,19.70151359033254,21.252018120443385,22.80252265055423,24.353027180665077,25.903531710775923,27.45403624088677,29.004540770997615,30.55504530110846,32.10554983121931,33.65605436133015,{"y":35.206558891441,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.05,16.05028658766154,17.050573175323077,18.050859762984615,19.051146350646153,20.05143293830769,21.051719525969233,22.052006113630767,23.05229270129231,24.052579288953844,25.052865876615385,26.05315246427692,27.05343905193846,{"y":28.0537256396,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.05,15.641029079003443,16.232058158006886,16.82308723701033,17.414116316013775,18.005145395017216,18.59617447402066,19.187203553024105,19.778232632027546,20.369261711030987,20.96029079003443,21.551319869037876,22.142348948041317,{"y":22.73337802704476,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.15,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >